Cardiovascular Drugs and Therapy

, Volume 21, Issue 4, pp 297–309 | Cite as

The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease

  • John B. KostisEmail author



Clinical management of two key modifiable risk factors for cardiovascular disease (CVD), hypertension and dyslipidemia, has evolved considerably over the past 40 years, in terms of the focus of therapy, available pharmacologic agents, and therapeutic targets.

Materials and methods

A brief review of the epidemiology of hypertension and hyperlipidemia and of controlled clinical trials of pharmacologic therapy of these conditions in decreasing cardiovascular events is presented.


Risk factors for CVD generally do not occur in isolation, and the co-occurrence of hypertension and dyslipidemia, with or without other additional risk factors, greatly increases the risk of CVD. Clinical trials performed in the last 40 years have demonstrated the clinical benefit of treating hypertension and dyslipidemia. Recent trials have shown that intensive, early management of these risk factors provide the greatest clinical benefits. Emerging evidence suggests that lipid management provides clinical benefit in patients at high risk of CVD, regardless of their baseline cholesterol levels, and that lipid-lowering with statin therapy provides additional benefits over antihypertensive therapy alone in high-risk patients with hypertension. It has become evident that the most effective means of reducing CVD risk is the simultaneous management of all modifiable risk factors. Treatment of an individual risk factor can reduce CVD events by approximately 30%, whereas treatment of multiple risk factors can reduce the risk of CVD by more than 50%. However, a large number of patients are not treated or receive suboptimal treatment.


Overwhelming controlled clinical trial evidence supports the clinical benefit of treating hypertension and hypercholesterolemia. Fixed-dose combination medications for hypertension, and integrative combination therapies containing antihypertensive and lipid-lowering medications in a single pill contribute to better risk factor management with the potential for greater adherence and improved clinical outcomes.

Key words

hypertension dyslipidemia statin combination therapy adherence 



Dr. John Kostis has received grant support from the NIH, Pfizer, Boehringer-Ingelheim, and Kos Pharmaceuticals. Editorial assistance was provided by Jon Edwards of Envision Pharma and funded by Pfizer Inc.


  1. 1.
    Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics—2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115:e69–171.PubMedCrossRefGoogle Scholar
  2. 2.
    Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56–64.PubMedCrossRefGoogle Scholar
  3. 3.
    O’Meara JG, Kardia SL, Armon JJ, Brown CA, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 2004;164:1313–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006;98:204–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002;23:528–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005;365:434–41.PubMedGoogle Scholar
  8. 8.
    National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.Google Scholar
  9. 9.
    Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. JAMA 2002;287:1003–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000;321:1322–5.PubMedCrossRefGoogle Scholar
  11. 11.
    White PD. Heart disease. New York: Macmillan, 1937.Google Scholar
  12. 12.
    Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028–34.Google Scholar
  13. 13.
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562–71.CrossRefGoogle Scholar
  14. 14.
    Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985;291:97–4.CrossRefGoogle Scholar
  15. 15.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255–64.CrossRefGoogle Scholar
  16. 16.
    Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) trial investigators. Lancet 1997;350:757–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000;160:211–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685–97.PubMedCrossRefGoogle Scholar
  20. 20.
    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.PubMedCrossRefGoogle Scholar
  22. 22.
    Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213–25.PubMedCrossRefGoogle Scholar
  24. 24.
    ALLHAT investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97.CrossRefGoogle Scholar
  25. 25.
    Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents—a preliminary report. Hypertension 2007;49:272–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527–35.PubMedCrossRefGoogle Scholar
  27. 27.
    Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410–9.PubMedCrossRefGoogle Scholar
  28. 28.
    JBS 2. Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1–v52.CrossRefGoogle Scholar
  29. 29.
    4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.Google Scholar
  30. 30.
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–22.PubMedCrossRefGoogle Scholar
  33. 33.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.CrossRefGoogle Scholar
  34. 34.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.CrossRefGoogle Scholar
  35. 35.
    Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–30.PubMedCrossRefGoogle Scholar
  36. 36.
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58.PubMedCrossRefGoogle Scholar
  37. 37.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–04.PubMedCrossRefGoogle Scholar
  38. 38.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35.PubMedCrossRefGoogle Scholar
  39. 39.
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.PubMedCrossRefGoogle Scholar
  40. 40.
    Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437–45.PubMedCrossRefGoogle Scholar
  41. 41.
    Alsheikh-Ali AA, Kuvin JT, Karas RH. High-density lipoprotein cholesterol in the cardiovascular equation: does the “good” still count? Atherosclerosis 2005;180:217–23.PubMedCrossRefGoogle Scholar
  42. 42.
    Rosenson RS. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 2005;118:1067–77.PubMedCrossRefGoogle Scholar
  43. 43.
    Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289–98.PubMedCrossRefGoogle Scholar
  44. 44.
    Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–92.PubMedCrossRefGoogle Scholar
  45. 45.
    Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Kuo PT, Hayase K, Kostis JB, Moreyra AE. Use of combined diet and colestipol in long-term (7–7 1/2 years) treatment of patients with type II hyperlipoproteinemia. Circulation 1979;59:199–211.PubMedGoogle Scholar
  47. 47.
    Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959–68.PubMedGoogle Scholar
  48. 48.
    MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998;97:1784–90.PubMedGoogle Scholar
  49. 49.
    Vigen C, Hodis HN, Selzer RH, Mahrer PR, Mack WJ. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study). Am J Cardiol 2005;95:1277–82.PubMedCrossRefGoogle Scholar
  50. 50.
    Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657–71.PubMedGoogle Scholar
  51. 51.
    Kostis JB. Disputation on the use of age in determining the need for treatment of hypercholesterolemia and hypertension. J Clin Hypertens (Greenwich) 2006;8:519–20.CrossRefGoogle Scholar
  52. 52.
    Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–80.PubMedCrossRefGoogle Scholar
  53. 53.
    Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556–65.PubMedCrossRefGoogle Scholar
  54. 54.
    Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998;44:1799–08.PubMedGoogle Scholar
  55. 55.
    Johnson ML, Pietz K, Battleman DS, Beyth RJ. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care 2004;10:926–32.PubMedGoogle Scholar
  56. 56.
    Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006;27:2982–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25:484–91.PubMedCrossRefGoogle Scholar
  58. 58.
    Wong ND, Lopez V, Tang S, Franklin SS, Williams GR. Coronary heart disease events preventable by control of blood pressure and lipids in U.S. persons with hypertension. J Am Coll Cardiol 2006;47:361A.CrossRefGoogle Scholar
  59. 59.
    Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000;35:539–43.PubMedGoogle Scholar
  60. 60.
    Kostis JB, Breazna A, LaRosa J, on behalf of the TNT Steering Committee and Investigators. The benefits of intensive lipid lowering in patients with stable CHD and systolic blood pressure above or below 140 mmHg: A post hoc analysis of the TNT study. J Clin Hypertens 2006;8:455.Google Scholar
  61. 61.
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.PubMedCrossRefGoogle Scholar
  62. 62.
    Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.PubMedCrossRefGoogle Scholar
  63. 63.
    Reddy KS. The preventive polypill—much promise, insufficient evidence. N Engl J Med 2007;356:212.PubMedCrossRefGoogle Scholar
  64. 64.
    Franco OH, Bonneux L, de Laet C, Peeters A, Steyerberg EW, Mackenbach JP. The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ 2004;329:1447–50.PubMedCrossRefGoogle Scholar
  65. 65.
    Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16–22.PubMedCrossRefGoogle Scholar
  66. 66.
    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96.PubMedCrossRefGoogle Scholar
  67. 67.
    Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006;145:520–30.PubMedGoogle Scholar
  68. 68.
    EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995–1001.CrossRefGoogle Scholar
  69. 69.
    Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Benner JS, Smith TW, Petrilla AA, Klingman D, Tang S. Coronary heart disease events and associated costs in US adults with uncontrolled hypertension and multiple cardiovascular risk factors. Poster Presented at the American Society of Hypertension 20th Annual Scientific Meeting and Exposition, 14–18 May, San Francisco, 2005.Google Scholar
  71. 71.
    Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147–52.PubMedCrossRefGoogle Scholar
  72. 72.
    Safran DG, Neuman P, Schoen C, Kitchman MS, Wilson IB, Cooper B, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood) 2005; Suppl Web Exclusives:W5-152-W5-166.Google Scholar
  73. 73.
    Soumerai SB, Pierre-Jacques M, Zhang F, Ross-Degnan D, Adams AS, Gurwitz J, et al. Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Arch Intern Med 2006;166:1829–35.PubMedCrossRefGoogle Scholar
  74. 74.
    Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9:2–6.PubMedGoogle Scholar
  75. 75.
    Chung M, Calcagni A, Glue P, Bramson C. Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 2006;46:1030–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Blank R, Lasalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the Amlodipine/Atorvastatin Gemini Study). J Clin Hypertens (Greenwich) 2005;7:264–73.CrossRefGoogle Scholar
  77. 77.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Alderman MH, Furberg CD, Kostis JB, Laragh JH, Psaty BM, Ruilope LM, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002;15:917–23.PubMedCrossRefGoogle Scholar
  79. 79.
    Volpe M, Alderman MH, Furberg CD, Jackson R, Kostis JB, Laragh JH, et al. Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens 2004;17:1068–74.PubMedGoogle Scholar
  80. 80.
    Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA 1977;237:255–61.CrossRefGoogle Scholar
  81. 81.
    The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980;140:1280–5.Google Scholar
  82. 82.
    The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984;144:1045–57.Google Scholar
  83. 83.
    The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988;148:1023–38.Google Scholar
  84. 84.
    The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154–83.Google Scholar
  85. 85.
    The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413–46.Google Scholar
  86. 86.
    National Cholesterol Education Program. Report of the National Education Program Expert on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36–69.Google Scholar
  87. 87.
    National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333–445.Google Scholar
  88. 88.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.Google Scholar
  89. 89.
    Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278–86.Google Scholar
  90. 90.
    Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633–8.Google Scholar
  91. 91.
    Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995;26:1133–9.Google Scholar
  92. 92.
    Jukema JW, Bruschke AV, van Boven AJ, Reiber JB, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528–40.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of MedicineUMDNJ-Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations